Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011-12-14 19:21 | 2011-12-12 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $39.10 | 5,787 | $226,272 | 51,266 | -10.1% |
| 2011-11-14 20:08 | 2011-11-11 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $37.55 | 5,700 | $214,035 | 57,053 | -9.1% |
| 2011-10-13 18:36 | 2011-10-11 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $38.10 | 5,700 | $217,170 | 62,753 | -8.3% |
| 2011-09-14 17:45 | 2011-09-12 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $35.91 | 5,700 | $204,687 | 68,453 | -7.7% |
| 2011-08-12 21:47 | 2011-08-11 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $33.94 | 5,700 | $193,458 | 74,298 | -7.1% |
| 2011-07-13 21:36 | 2011-07-11 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $37.39 | 5,700 | $213,123 | 79,998 | -6.7% |
| 2011-06-15 16:45 | 2011-06-13 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $37.25 | 5,700 | $212,325 | 86,307 | -6.2% |
| 2011-05-13 16:15 | 2011-05-11 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $38.21 | 5,700 | $217,797 | 92,007 | -5.8% |
| 2011-04-12 22:30 | 2011-04-11 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $35.76 | 5,700 | $203,832 | 97,707 | -5.5% |
| 2011-02-18 00:34 | 2011-02-16 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $34.49 | 3,100 | $106,919 | 103,407 | -2.9% |
| 2011-01-18 21:24 | 2011-01-14 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $34.87 | 3,100 | $108,097 | 56,930 | -5.2% |
| 2010-12-17 23:54 | 2010-12-16 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $35.10 | 3,100 | $108,810 | 60,030 | -4.9% |
| 2010-11-17 22:10 | 2010-11-16 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $34.43 | 3,100 | $106,733 | 63,340 | -4.7% |
| 2010-10-19 20:16 | 2010-10-15 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $37.65 | 3,100 | $116,715 | 66,440 | -4.5% |
| 2010-09-17 22:16 | 2010-09-16 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $35.55 | 3,100 | $110,205 | 69,540 | -4.3% |
| 2010-08-18 19:32 | 2010-08-16 | LLY | ELI LILLY & Co | Carmine Bryce D. | Officer; EVP and Pres, Lilly Bio-Meds | Pharmaceutical Preparations | SALE | $35.33 | 3,100 | $109,523 | 72,640 | -4.1% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.